Clorox Gestione
Criteri Gestione verificati 4/4
Clorox Il CEO è Linda Rendle, nominato in Sep2020, e ha un mandato di 5.67 anni. la retribuzione annua totale è $ 13.33M, composta da 9.8% di stipendio e 90.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.025% delle azioni della società, per un valore di $ 2.88M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.7 anni e 5.7 anni.
Informazioni chiave
Linda Rendle
Amministratore delegato
US$13.3m
Compenso totale
| Percentuale dello stipendio del CEO | 9.81% |
| Mandato del CEO | 5.7yrs |
| Proprietà del CEO | 0.03% |
| Durata media del management | 4.7yrs |
| Durata media del Consiglio di amministrazione | 5.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • May 14
CLX: GOJO Integration And Need Based Focus Will Support Long Term Earnings
Analysts have trimmed the blended fair value estimate for Clorox to about $144 from roughly $155, as a series of firms cut price targets, citing refreshed views on growth, margins, and future P/E multiples following recent research updates. Analyst Commentary Recent research has been dominated by cuts to fair value estimates and price targets, yet there are still some constructive signals in the commentary that matter if you are focused on Clorox's long term setup rather than just near term P/E compression.
Aggiornamento della narrazione • Apr 29
CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple
Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.Seeking Alpha • Apr 28
Clorox: Reduced Complexity Paves The Way For Multiple Expansion
Summary Clorox is attractively valued after underperformance, offering a 5% dividend yield and normalization post-cyber attack and ERP disruptions. The recent Purell (GOJO) acquisition is set to be accretive to EBITDA and EPS by FY27, supporting top-line growth above the company's long-term algorithm. CLX trades at 14.5x FY27 EPS, with double-digit earnings growth and room for multiple expansion relative to peers, setting up 20% upside potential. Risks include high customer concentration, private label competition, and consumer value-seeking behavior, but strong cash flow supports deleveraging and dividend sustainability. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 15
CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power
Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.Aggiornamento della narrazione • Mar 31
CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power
Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.Aggiornamento della narrazione • Mar 17
CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook
Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.Aggiornamento della narrazione • Mar 03
CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power
Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.Aggiornamento della narrazione • Feb 17
CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E
The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.Aggiornamento della narrazione • Feb 03
CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple
Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.Aggiornamento della narrazione • Jan 20
CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating
Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.Aggiornamento della narrazione • Jan 05
CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating
Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.Aggiornamento della narrazione • Dec 20
CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook
Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.Aggiornamento della narrazione • Dec 05
CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery
Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.Aggiornamento della narrazione • Nov 21
CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026
Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.Articolo di analisi • Nov 12
Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet
Key Insights Clorox will host its Annual General Meeting on 19th of November Total pay for CEO Linda Rendle includes...Articolo di analisi • Nov 10
Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues
The market shrugged off The Clorox Company's ( NYSE:CLX ) solid earnings report. We did some digging and believe...Aggiornamento della narrazione • Nov 06
CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026
Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.Aggiornamento della narrazione • Oct 23
Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook
Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.Aggiornamento della narrazione • Oct 09
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.Aggiornamento della narrazione • Aug 27
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.Articolo di analisi • Aug 04
Clorox (NYSE:CLX) Has Announced That It Will Be Increasing Its Dividend To $1.24
The Clorox Company ( NYSE:CLX ) will increase its dividend on the 29th of August to $1.24, which is 1.6% higher than...Articolo di analisi • Aug 02
Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...Articolo di analisi • Jul 16
Returns On Capital At Clorox (NYSE:CLX) Have Stalled
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Seeking Alpha • Mar 29
Clorox: Reviving From Cyberattack; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Clorox with a fair value of $153 per share, driven by strong brand equity and IT modernization efforts. Clorox's ERP upgrade and IT investments are expected to drive future growth, despite near-term costs and recent cyberattack impacts. Clorox anticipates 3%-5% organic revenue growth and 13%-19% adjusted EPS growth in FY25, supported by new ERP system rollout and cost management. Key risks include Walmart's pricing power, potential consumer shift to private labels, and tariff exposure, though mitigated by supply chain adjustments. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Clorox: A Wonderful Business I Would Like To Own At A Lower Price
Summary Clorox is a wonderful business that sells everyday products across the world. It has many well-loved brands that customers love. The company has bounced back from the cyberattack it suffered in 2023, and has regained lost market share and improved margins. Wallstreet analysts across the board have upgraded their earnings expectations for CLX. However, there are real concerns facing it, and I do not think that investing in CLX at the current price offers me a favorable risk-reward scenario. Read the full article on Seeking AlphaSeeking Alpha • Nov 26
The Clorox Company: Hold, Trading Above Fair Value Despite Positive Signals
Summary I rate The Clorox Company a hold due to its volatile financial performance and current stock trading above fair value. Despite revenue fluctuations, Clorox has strong brand recognition and promising growth potential, with 80% of sales from top-ranked products. The company's resilience is evident through consistent dividends, high ROE, ROCE, and positive EVA, indicating shareholder value creation. Clorox's recovery is marked by significant YoY growth in revenue, net income, and operational efficiency, showcasing potential for future growth. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$756m |
| Dec 31 2025 | n/a | n/a | US$755m |
| Sep 30 2025 | n/a | n/a | US$791m |
| Jun 30 2025 | US$13m | US$1m | US$810m |
| Mar 31 2025 | n/a | n/a | US$694m |
| Dec 31 2024 | n/a | n/a | US$457m |
| Sep 30 2024 | n/a | n/a | US$357m |
| Jun 30 2024 | US$13m | US$1m | US$280m |
| Mar 31 2024 | n/a | n/a | US$240m |
| Dec 31 2023 | n/a | n/a | US$80m |
| Sep 30 2023 | n/a | n/a | US$86m |
| Jun 30 2023 | US$12m | US$1m | US$149m |
| Mar 31 2023 | n/a | n/a | US$74m |
| Dec 31 2022 | n/a | n/a | US$435m |
| Sep 30 2022 | n/a | n/a | US$405m |
| Jun 30 2022 | US$9m | US$1m | US$462m |
| Mar 31 2022 | n/a | n/a | US$458m |
| Dec 31 2021 | n/a | n/a | US$247m |
| Sep 30 2021 | n/a | n/a | US$437m |
| Jun 30 2021 | US$8m | US$1m | US$710m |
| Mar 31 2021 | n/a | n/a | US$923m |
| Dec 31 2020 | n/a | n/a | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | US$2m | US$524k | US$939m |
| Mar 31 2020 | n/a | n/a | US$870m |
| Dec 31 2019 | n/a | n/a | US$816m |
| Sep 30 2019 | n/a | n/a | US$813m |
| Jun 30 2019 | US$2m | US$436k | US$820m |
Compensazione vs Mercato: La retribuzione totale di Linda ($USD 13.33M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 14.80M ).
Compensazione vs guadagni: La retribuzione di Linda è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Linda Rendle (46 yo)
5.7yrs
Mandato
US$13,333,032
Compensazione
Ms. Linda J. Rendle serves as Independent Director at Visa Inc. since January 23,2020. She serves as Chief Executive Officer and Director of The Clorox Company since September 14 2020 & serves as January 1...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 5.7yrs | US$13.33m | 0.025% $ 2.9m | |
| Executive VP & CFO | 1.1yrs | US$2.62m | 0.0093% $ 1.1m | |
| Executive VP and Group President of Health & Hygiene | 4.7yrs | US$4.37m | 0.0090% $ 1.0m | |
| Executive VP and Group President of Care & Connection | 1.8yrs | US$10.07m | 0.0029% $ 331.7k | |
| VP, Chief Accounting Officer & Corporate Controller | 5yrs | Nessun dato | 0.0036% $ 410.3k | |
| Senior VP and Chief Information & Data Officer | 5.9yrs | Nessun dato | Nessun dato | |
| Executive VP & Chief Administrative Officer | 1.1yrs | US$3.54m | 0.019% $ 2.2m | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Executive VP | 20.8yrs | US$3.45m | 0.013% $ 1.5m | |
| Senior VP & Chief Marketing Officer | 4.2yrs | Nessun dato | Nessun dato | |
| Chief Diversity Officer | 19.9yrs | Nessun dato | Nessun dato | |
| Executive VP and Executive Chief of Staff | 4.2yrs | US$3.56m | 0.0066% $ 752.3k |
4.7yrs
Durata media
51.5yo
Età media
Gestione esperta: Il team dirigenziale di CLX è considerato esperto (durata media dell'incarico 4.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 5.7yrs | US$13.33m | 0.025% $ 2.9m | |
| Independent Director | 9.8yrs | US$270.00k | 0.00050% $ 57.0k | |
| Independent Director | 10.8yrs | US$292.18k | 0.00070% $ 79.8k | |
| Independent Director | 1yr | US$12.40k | Nessun dato | |
| Independent Director | 12.8yrs | US$285.00k | Nessun dato | |
| Lead Independent Director | 7.8yrs | US$370.00k | Nessun dato | |
| Independent Director | 9.3yrs | US$272.25k | Nessun dato | |
| Independent Director | 1.5yrs | US$149.80k | 0.015% $ 1.7m | |
| Independent Director | 1.5yrs | US$146.98k | Nessun dato | |
| Independent Director | 4yrs | US$270.00k | Nessun dato | |
| Independent Director | 4yrs | US$270.00k | Nessun dato |
5.7yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CLX sono considerati esperti (durata media dell'incarico 5.7 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 22:50 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/06/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
The Clorox Company è coperta da 34 analisti. 14 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John Staszak | Argus Research Company |
| Lauren Lieberman | Barclays |
| Lauren Lieberman | Barclays |